VolitionRx announced a new commercialization strategy for the US with its FY15 results. The company will seek a 510(k) approval in the US as an intermediate step to eventual PMA approval. This will allow for a quicker commercial launch of the NuQ colorectal test in the US, but would limit its marketing to “informing” a physician’s diagnosis instead of being a definitive diagnostic tool. The nearest-term revenues are in Europe, where a CE-mark approval and commercial launch a
01 Apr 2016
Closing in on commercialization
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Closing in on commercialization
VolitionRx announced a new commercialization strategy for the US with its FY15 results. The company will seek a 510(k) approval in the US as an intermediate step to eventual PMA approval. This will allow for a quicker commercial launch of the NuQ colorectal test in the US, but would limit its marketing to “informing” a physician’s diagnosis instead of being a definitive diagnostic tool. The nearest-term revenues are in Europe, where a CE-mark approval and commercial launch a